Tempus AI (NASDAQ:TEM) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Tempus AI (NASDAQ:TEM) posted its earnings results on Tuesday. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01, FiscalAI reports. The company had revenue of $367.21 million for the quarter, compared to analysts’ expectations of $362.55 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%.

Tempus AI Stock Up 1.2%

NASDAQ TEM traded up $0.66 during trading hours on Tuesday, hitting $57.95. 4,981,486 shares of the company were exchanged, compared to its average volume of 5,650,480. The company has a 50 day moving average of $62.13 and a two-hundred day moving average of $73.61. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. Tempus AI has a 52-week low of $36.22 and a 52-week high of $104.32. The firm has a market cap of $10.31 billion, a price-to-earnings ratio of -48.70 and a beta of 5.22.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Launched HRD‑RNA and added lung‑cancer screening via a Median Technologies partnership — broadens Tempus’s clinical offerings for treatment selection and early detection, supporting future revenue diversification and cross‑sell into oncology workflows. Tempus AI Expands Cancer Workflow With HRD-RNA Launch And Lung Screening
• Positive Sentiment: Imaging push gains traction — analysts note the Median deal and prior FDA clearances strengthen Tempus’s move into radiology/AI imaging, which could increase Pixel platform adoption and create new revenue streams. Here’s How Tempus AI Is Tapping the Imagining Space
• Neutral Sentiment: Earnings preview — analysts and previews flag key items investors will watch in the print: revenue growth, margin progress, guidance, and product monetization (testing, Pixel imaging uptake). The report sets expectations that could drive post‑report volatility. What’s Next: Tempus AI’s Earnings Preview
• Neutral Sentiment: Live earnings coverage in play — real‑time updates and market reaction are being tracked; results or guidance surprises are the most likely immediate drivers of today’s price action. Live Earnings: Will Tempus AI Surprise Wall Street Tonight?
• Negative Sentiment: Significant insider selling reported — multiple senior executives (CEO, CFO, and EVPs) sold shares on 2/23, totaling roughly $2.9M of disclosed sales; large, clustered insider sales can raise investor concern about insider confidence or signal personal liquidity moves. Tempus AI (NASDAQ:TEM) CEO Sells $566,407.60 in Stock Tempus AI (NASDAQ:TEM) CFO Sells $595,460.20 in Stock Tempus AI (NASDAQ:TEM) EVP Sells $660,334.19 in Stock

Insiders Place Their Bets

In other news, CEO Ryan Fukushima sold 9,592 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the transaction, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at approximately $41,001,603.70. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Erik Phelps sold 9,464 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total transaction of $562,445.52. Following the sale, the executive vice president owned 79,816 shares in the company, valued at $4,743,464.88. The trade was a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 596,035 shares of company stock worth $37,505,125. Corporate insiders own 26.27% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently modified their holdings of TEM. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI during the 3rd quarter worth $26,000. Los Angeles Capital Management LLC acquired a new stake in Tempus AI in the fourth quarter valued at $27,000. Harvest Fund Management Co. Ltd purchased a new stake in Tempus AI during the 3rd quarter worth about $38,000. Danske Bank A S acquired a new position in shares of Tempus AI during the 3rd quarter worth about $48,000. Finally, Sunbelt Securities Inc. purchased a new position in shares of Tempus AI in the 3rd quarter valued at about $52,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on TEM shares. BTIG Research boosted their price target on shares of Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Piper Sandler cut their target price on Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Robert W. Baird initiated coverage on Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective for the company. Finally, Needham & Company LLC boosted their price objective on Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Eight analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $85.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.